Neuropeptides
Volume 44, Issue 2 , Pages 139-143 , April 2010

Plasma Kallikrein and Angiotensin I-converting enzyme N- and C-terminal domain activities are modulated by the insertion/deletion polymorphism

  • S.S. Almeida

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • ,
  • C.C. Barros

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • ,
  • M.R. Moraes

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • ,
  • F.J. Russo

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • ,
  • A.S. Haro

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • ,
  • T.S. Rosa

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • ,
  • M.F. Alves

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • ,
  • J.B. Pesquero

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • ,
  • A.K. Carmona

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • ,
  • R.F.P. Bacurau

      Affiliations

    • School of Arts, Sciences and Humanities – USP, Brazil
    • ,
  • R.C. Araújo

      Affiliations

    • Department of Biophysics, Federal University of São Paulo, Brazil
    • Corresponding Author InformationCorresponding author. Address: Rua Botucatu, 862 - 7° Andar, Vila Clementino, 04023-062 São Paulo – SP, Brazil. Tel.: +55 11 55764530; fax: +55 11 55715780.

References 

  1. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM, Corvol P. Distribution of plasma angiotensin I-converting enzyme levels in healthy men: relationship to environmental and hormonal parameters. J. Lab. Clin. Med. 1991;117:33–39
  2. Alvarez R, Terrados N, Ortolano R, Iglesias-Cubero G, Reguero JR, Batalla A, et al. Genetic variation in the renin–angiotensin system and athletic performance. Eur. J. Appl. Physiol. 2000;82:117–120
  3. Alves MF, Araujo MC, Juliano MA, Oliveira EM, Krieger JE, Casarini DE, et al. A continuous fluorescent assay for the determination of plasma and tissue angiotensin I-converting enzyme activity. Braz. J. Med. Biol. Res. 2005;38:861–868
  4. Araujo MC, Melo RL, Cesari MH, Juliano MA, Juliano L, Carmona AK. Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry. 2000;39:8519–8525
  5. Azizi M, Junot C, Ezan E, Hallouin MC, Guyene T, Menard J. Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production. J. Mol. Med. 2002;80:492–498
  6. Carmona AK, Schwager SL, Juliano MA, Juliano L, Sturrock ED. A continuous fluorescence resonance energy transfer angiotensin I-converting enzyme assay. Nat. Protoc. 2006;1:1971–1976
  7. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.. Circulation. 1995;92:1387–1388
  8. Dorer FE, Kahn JR, Lentz KE, Levine M, Skeggs LT. Hydrolysis of bradykinin by angiotensin-converting enzyme. Circ. Res. 1974;34:824–827
  9. Ehlers MR, Fox EA, Strydom DJ, Riordan JF. Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc. Natl. Acad. Sci. USA. 1989;86:7741–7745
  10. Foschini, D., Araujo, R.C., Bacurau, R.F., De Piano, A., De Almeida, S.S., Carnier, J., Rosa, T.D., De Mello, M.T., Tufik, S., Damaso, A.R., 2009. Treatment of obese adolescents: the influence of periodization models and ACE genotype. Obesity (Silver Spring).
  11. Henriques OB, Allan L. Glass activated kallikrein from human plasma. Biochem. Pharmacol. 1972;21:3163–3169
  12. Jalil JE, Cordova S, Ocaranza M, Schumacher E, Braun S, Chamorro G, et al. Angiotensin I-converting enzyme insertion/deletion polymorphism and adrenergic response to exercise in hypertensive patients. Med. Sci. Monit. 2002;8:CR566–571
  13. Jalil JE, Piddo AM, Cordova S, Chamorro G, Braun S, Jalil R, et al. Prevalence of the angiotensin I converting enzyme insertion/deletion polymorphism, plasma angiotensin converting enzyme activity, and left ventricular mass in a normotensive Chilean population. Am. J. Hypertens. 1999;12:697–704
  14. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II) Studies with bradykinin and other natural peptides.. J. Biol. Chem. 1993;268:9496–9503
  15. Jones A, Woods DR. Skeletal muscle RAS and exercise performance. Int. J. Biochem. Cell Biol. 2003;35:855–866
  16. Kakoki M, Smithies O. The kallikrein–kinin system in health and in diseases of the kidney. Kidney Int. 2009;75:1019–1030
  17. Lachurie ML, Azizi M, Guyene TT, Alhenc-Gelas F, Menard J. Angiotensin–converting enzyme gene polymorphism has no influence on the circulating renin–angiotensin–aldosterone system or blood pressure in normotensive subjects. Circulation. 1995;91:2933–2942
  18. Lottenberg R, Christensen U, Jackson CM, Coleman PL. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol. 1981;80 Pt C:341–361
  19. Montgomery H, Clarkson P, Barnard M, Bell J, Brynes A, Dollery C, et al. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet. 1999;353:541–545
  20. Moraes MR, Bacurau RF, Ramalho JD, Reis FC, Casarini DE, Chagas JR, et al. Increase in kinins on post-exercise hypotension in normotensive and hypertensive volunteers. Biol. Chem. 2007;388:533–540
  21. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation. 2000;102:829–832
  22. Myerson S, Hemingway H, Budget R, Martin J, Humphries S, Montgomery H. Human angiotensin I-converting enzyme gene and endurance performance. J. Appl. Physiol. 1999;87:1313–1316
  23. O’Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation. 1998;97:1766–1772
  24. Okada Y, Tsuda Y, Tada M, Wanaka K, Hijikata-Okunomiya A, Okamoto U, et al. Development of plasma kallikrein selective inhibitors. Biopolymers. 1999;51:41–50
  25. Omran S, Hallouda M, Essawi F, el Attar I, Aboul Enein A, Gaafar T, et al. Effect of cold storage on the haemostatic cascade systems. Transfus. Sci. 1996;17:407–414
  26. Pontes FL, Bacurau RF, Moraes MR, Navarro F, Casarini DE, Pesquero JL, et al. Kallikrein -kinin system activation in post-exercise hypotension in water running of hypertensive volunteers. Int. Immunopharmacol. 2008;8:261–266
  27. Rankinen T, Wolfarth B, Simoneau JA, Maier-Lenz D, Rauramaa R, Rivera MA, et al. No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. J. Appl. Physiol. 2000;88:1571–1575
  28. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 1990;86:1343–1346
  29. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 1995;270:3656–3661
  30. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl. 1993;3:120–121
  31. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL, et al. Exploration of myostatin polymorphisms and the angiotensin-converting enzyme insertion/deletion genotype in responses of human muscle to strength training. Eur. J. Appl. Physiol. 2004;92:267–274
  32. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. 1992;51:197–205
  33. Topouchian JA, El Assaad MA, Orobinskaia LV, El Feghali RN, Asmar RG. Validation of two devices for self-measurement of brachial blood pressure according to the International Protocol of the European Society of Hypertension: the SEINEX SE-9400 and the Microlife BP 3AC1–1. Blood Press. Monit. 2005;10:325–331
  34. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation. 2005;112:1743–1747
  35. van Esch JH, van Gool JM, de Bruin RJ, Payne JR, Montgomery HE, Hectors M, et al. Different contributions of the angiotensin-converting enzyme C- and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype. J. Hypertens. 2008;26:706–713
  36. Wanaka K, Okamoto S, Bohgaki M, Hijikata-Okunomiya A, Naito T, Okada Y. Effect of a highly selective plasma-kallikrein synthetic inhibitor on contact activation relating to kinin generation, coagulation and fibrinolysis. Thromb. Res. 1990;57:889–895
  37. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 1991;266:9002–9008
  38. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J. Biol. Chem. 1992;267:13398–13405
  39. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S, Montgomery HE. Circulating angiotensin converting enzyme activity is correlated with muscle strength. Med. Sci. Sports Exerc. 2005;37:944–948
  40. Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim. Biophys. Acta. 1970;214:374–376
  41. Yang N, MacArthur DG, Gulbin JP, Hahn AG, Beggs AH, Easteal S, et al. ACTN3 genotype is associated with human elite athletic performance. Am. J. Hum. Genet. 2003;73:627–631

PII: S0143-4179(09)00142-5

doi: 10.1016/j.npep.2009.12.003

Neuropeptides
Volume 44, Issue 2 , Pages 139-143 , April 2010

Article Tools

* Image Usage & Resolution